CollPlant Biotechnologies Ltd.
CLGNNASDAQHealthcare● Active
$0.37
$-0.00(-0.27%)
Market Cap$4522010
P/E Ratio—
52W High$3.232
52W Low$0.271
CollPlant Biotechnologies Ltd. (CLGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLGN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.37M | $0.52M | $10.96M | $0.30M | $15.64M |
| Cost of Revenue | $1.75M | $2.66M | $3.09M | $1.48M | $2.00M |
| Gross Profit | $0.62M | ($2.15M) | $7.87M | ($1.18M) | $13.64M |
| Gross Margin %(computed) | 26.32% | -417.09% | 71.78% | -393.65% | 87.18% |
| Operating Expenses | |||||
| R&D Expenses | $8.19M | $10.52M | $10.48M | $10.26M | $7.63M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $12.11M | $15.10M | $15.38M | $15.92M | $13.57M |
| Operating Income | ($11.48M) | ($17.25M) | ($7.51M) | ($17.10M) | $0.07M |
| Operating Margin %(computed) | -484.31% | — | -68.55% | — | 0.42% |
| Interest Income | $0.38M | $0.74M | $0.79M | $0.32M | $0.22M |
| Interest Expense | $0.01M | $0.02M | $0.01M | $0.03M | $0.04M |
| Income Before Tax | ($11.49M) | ($16.61M) | ($7.02M) | ($16.93M) | $0.24M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($11.49M) | ($16.61M) | ($7.02M) | ($16.93M) | $0.24M |
| Net Margin %(computed) | -484.56% | — | -64.05% | — | 1.52% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.94 | $-1.45 | $-0.62 | $-1.52 | $0.04 |
| Wtd Avg Shares | 12.20M | 11.45M | 11.39M | 11.03M | 9.97M |
| EBITDA | ($10.57M) | ($15.55M) | ($5.91M) | ($15.81M) | $1.05M |
| EBITDA Margin %(computed) | -445.85% | — | -53.90% | — | 6.69% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more CollPlant Biotechnologies Ltd. data
About CollPlant Biotechnologies Ltd. (CLGN) Income Statement
CollPlant Biotechnologies Ltd. (CLGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CLGN reported revenue of $0.00B, gross profit of $0.00B (gross margin 26.32%), and net income of ($0.01B) — a net profit margin of -484.56%.
Frequently asked questions
CLGN · 4 questionsCollPlant Biotechnologies Ltd. (CLGN) reported revenue of $0.00B for 2025, up 360.4% year-over-year.
CLGN revenueCLGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09